Rep. April McClain Delaney Sells Off Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Posted by ABMN Staff on Feb 4th, 2026

Representative April McClain Delaney (D-Maryland) recently sold shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in IDEXX Laboratories stock on January 13th.

Representative April McClain Delaney also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/30/2026.
Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/30/2026.
Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/29/2026.
Sold $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 1/28/2026.
Sold $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 1/28/2026.
Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/28/2026.
Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 1/28/2026.
Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/23/2026.
Sold $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 1/22/2026.
Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/22/2026.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $632.56 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average price is $700.41 and its two-hundred day moving average price is $663.48. The company has a market cap of $50.51 billion, a PE ratio of 48.40, a price-to-earnings-growth ratio of 3.41 and a beta of 1.67. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company posted $2.53 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

Positive Sentiment: IDXX beat Q4 expectations — reported $3.08 EPS vs. $2.93 consensus and $1.091B revenue, with margins improving and double-digit year-over-year revenue growth; this underscores resilient demand in core diagnostics. Business Wire: IDEXX Announces Fourth Quarter and Full-Year 2025 Results
Positive Sentiment: Companion Animal Group (CAG) and Water businesses showed strong growth (CAG ~15% reported; Water ~12%), and management highlighted innovation and higher tests per visit as growth drivers — supporting mid/long-term revenue expansion. Seeking Alpha: Idexx targets $4.632B–$4.720B revenue for 2026
Neutral Sentiment: Management issued FY2026 guidance (EPS range 14.290–14.800, revenue $4.6B–$4.7B); the EPS range is roughly in line with Street expectations while revenue guidance is at/just below consensus, leaving room for interpretation. Reuters: IDEXX forecasts 2026 revenue, profit above estimates
Neutral Sentiment: Full earnings call transcripts and slide deck are available; management commentary reiterates innovation-led growth and clinic testing intensity as key assumptions — useful for modeling but not immediately market-moving. MSN: IDEXX Q4 2025 earnings call transcript
Negative Sentiment: Some analysts trimmed forecasts after the print and guidance, signaling lowered near-term expectations and prompting downward pressure on the stock. Benzinga: Analysts Cut Their Forecasts Following Q4 Results
Negative Sentiment: Market reaction focused on the outlook: despite a beat, commentary and the revenue range prompted investors to pare positions, with coverage noting shares trimmed on the guidance nuance. MSN: IDEXX tops revenue forecasts, shares edge lower on outlook

Insider Buying and Selling

In other news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in IDEXX Laboratories by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after acquiring an additional 86,040 shares in the last quarter. Geode Capital Management LLC increased its position in shares of IDEXX Laboratories by 2.3% in the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after purchasing an additional 54,402 shares during the period. Bank of New York Mellon Corp raised its stake in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after purchasing an additional 605,290 shares in the last quarter. Invesco Ltd. lifted its position in IDEXX Laboratories by 14.0% during the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after purchasing an additional 161,782 shares during the period. Finally, Principal Financial Group Inc. grew its stake in IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after buying an additional 187,967 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. BTIG Research dropped their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Barclays started coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective for the company. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

View Our Latest Research Report on IDXX

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.